Which drugs have a proven causal link to fetal cleft palate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications with Proven Links to Cleft Palate

Methotrexate has the strongest evidence for causing cleft palate, with a 2.6-fold increased risk of oral clefts when used during pregnancy, and must be discontinued at least 3-6 months before conception 1, 2, 1.

Medications with Established Teratogenic Risk for Cleft Palate

High-Risk Medications (Absolute Contraindications)

Methotrexate is the most clearly documented medication linked to cleft palate:

  • 2.6-fold increased risk of oral clefts compared to no exposure 1
  • Also causes 3.4-fold increased risk of cardiovascular defects 1
  • Must be stopped at least 3 months before conception (some guidelines recommend 6 months) 2, 1
  • If pregnancy occurs while taking methotrexate: immediately discontinue and refer for obstetric counseling 1
  • Folic acid supplementation should be initiated or continued to reduce methotrexate-related adverse effects 1

Antiepileptic Drugs (AEDs)

Valproic acid carries significant risk:

  • 11.9-fold increased risk for spina bifida 3
  • 5.8-fold increased risk for cleft palate 3
  • Approximately 35 infants per year in the US could be born without cleft palate if valproic acid were avoided during pregnancy 3

Carbamazepine has moderate risk:

  • 2.4-fold increased risk for cleft palate 3
  • Confirmed cleft-inducing effect in multiple studies 4
  • Approximately 5 infants per year in the US could be born without cleft palate if carbamazepine were avoided 3

Phenytoin is also associated with cleft palate:

  • Confirmed orofacial cleft-inducing effect 5, 4
  • 2.6%-6.4% risk of major congenital malformations 5
  • Specific teratogenic risk for cardiac defects, cleft palate, and club foot 5

Phenobarbital:

  • 5.5%-6.5% teratogenic risk 5
  • Higher risk when doses exceed 80 mg/day 5

Corticosteroids

Systemic corticosteroids (prednisolone, prednisone) have conflicting but concerning data:

  • Some studies show 3-fold increased risk for isolated cleft lip ± cleft palate when used in first trimester 6, 7
  • However, newer studies and registries suggest glucocorticoids may not pose teratogenic risk for orofacial clefts 2
  • The evidence remains mixed, but caution is warranted in first trimester use 6, 7
  • When severe asthma or autoimmune disease requires treatment, the maternal benefit may outweigh fetal risk 6

Antihistamines (Uncertain/Low Risk)

Diphenhydramine has some concern:

  • One case-control study suggested association with cleft palate 8
  • However, recent larger studies have not detected increased risk 8
  • The concern has "yet to be sufficiently refuted" 8
  • Most antihistamines show excellent safety records overall 8

Hydroxyzine:

  • Should be used cautiously in first trimester based on animal data 8

Ondansetron (Minimal Risk)

Ondansetron has very small absolute risk:

  • Absolute risk of orofacial clefting increases from 11 cases per 10,000 births to 14 cases per 10,000 births 9
  • This represents only 3 additional cases per 10,000 births 9
  • Most robust studies (>88,000 first trimester exposures) show no overall increased malformation rate 9
  • The small increased risk should be balanced against risks of poorly managed hyperemesis gravidarum 9

Clinical Algorithm for Medication Management

Preconception Planning:

  1. Stop methotrexate 3-6 months before attempting conception 2, 1
  2. Switch from valproic acid to safer alternatives (levetiracetam or lamotrigine preferred) 5
  3. Minimize or switch from carbamazepine/phenytoin if possible 5, 3
  4. Use monotherapy at lowest effective dose for seizure disorders 10

First Trimester Exposure:

  • Methotrexate: Immediate discontinuation, folic acid supplementation, obstetric counseling (termination not mandatory) 1
  • Valproic acid/carbamazepine: Switch to safer AED if seizure control allows 5
  • Systemic corticosteroids: Weigh maternal disease severity against small cleft risk 6, 7

Common Pitfalls to Avoid:

  • Do not assume all antihistamines carry equal risk—most are safe 8
  • Do not avoid ondansetron unnecessarily in severe hyperemesis—the absolute risk increase is minimal 9
  • Do not stop corticosteroids abruptly in severe asthma or autoimmune disease—uncontrolled maternal disease poses greater fetal risk 6
  • Do not use polytherapy for seizures when monotherapy is possible 10

References

Research

Drug treatment during pregnancy and isolated orofacial clefts in hungary.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association, 2007

Guideline

the diagnosis and management of rhinitis: an updated practice parameter.

Journal of Allergy and Clinical Immunology, 2008

Guideline

the management of nausea and vomiting in pregnancy and hyperemesis gravidarum (green-top guideline no. 69).

BJOG : an international journal of obstetrics and gynaecology, 2024

Guideline

recommendations for preconception counseling and care.

American family physician, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.